Suzetrigine

Last updated

Suzetrigine
Suzetrigine.svg
Suzetrigine 3D structure.png
Clinical data
Pronunciation /suˈzɛtrɪdʒiːn/
soo-ZE-tri-jeen
Trade names Journavx
Other namesVX-548
AHFS/Drugs.com Monograph
MedlinePlus a625039
License data
Routes of
administration 		By mouth
Drug class Nav1.8 sodium channel blocker; Analgesic
ATC code
  • None
Legal status
Legal status
Identifiers
  • 4-{{#parsoidfragment:6}}(2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C21H20F5N3O4
Molar mass 473.400 g·mol−1
3D model (JSmol)
  • COc1c([C@H]2[C@H](C(=O)Nc3ccnc(C(N)=O)c3)O[C@@](C)(C(F)(F)F)[C@H]2C)ccc(F)c1F
  • InChI=1S/C21H20F5N3O4/c1-9-14(11-4-5-12(22)15(23)16(11)32-3)17(33-20(9,2)21(24,25)26)19(31)29-10-6-7-28-13(8-10)18(27)30/h4-9,14,17H,1-3H3,(H2,27,30)(H,28,29,31)/t9-,14-,17-,20-/m0/s1
  • Key:XSQUJFKRXZMOKA-PAFIKIDNSA-N

Suzetrigine, sold under the brand name Journavx, is a medication used for pain management. [1] [2] It is a small-molecule non-opioid analgesic that works as a selective inhibitor of Nav1.8-dependent pain-signaling pathways in the peripheral nervous system. [3] [4] It is not addictive. Suzetrigine is taken by mouth. [1]

Contents

Suzetrigine was developed by Vertex Pharmaceuticals. [5] It was approved for medical use in the United States in January 2025. [2] [6] Suzetrigine is the first medication to be approved by the US Food and Drug Administration (FDA) in this class of medicines. [2]

Medical uses

Suzetrigine is indicated for the treatment of moderate to severe acute pain in adults. [1] [2]

Efficacy

In clinical studies conducted through 2024, suzetrigine reduced pain typically from 7 to 4 on the standard numeric scale used to rate pain. [7] [8] The efficacy of suzetrigine was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, one following abdominoplasty and the other following bunionectomy. [2] Both trials found that suzetrigine reduced pain more effectively than placebo. [2]

However, in clinical studies, no superiority over hydrocodone and paracetamol (acetaminophen) in terms of pain reduction was shown. [9] Medical professionals have noted its efficacy may be inferior to high-dose opioid analgesics. [10] There are no studies comparing suzetrigine with high-dose opioids. Most patients in clinical trials required rescue NSAID administration. Suzetrigine exhibits CYP3A4-mediated drug interactions and there is limited long-term data regarding its use. [11] Moreover, its cost-effectiveness is disputed. [12]

Contraindications

Concomitant use of suzetrigine with strong CYP3A4 inhibitors is contraindicated. [1] [2]

Adverse effects

Common adverse effects of suzetrigine may include itching, rash, muscle spasms, and increased levels of creatine kinase. [2] Mild side effects may include nausea, constipation, headache, and dizziness. [7] [8] As of 2024, long-term safety and side effects remain undetermined. [8]

In preliminary research, suzetrigine had no serious neurological, behavioral, or cardiovascular effects. [3]

Interactions

Consuming grapefruit while using suzetrigine may cause adverse grapefruit–drug interactions. [1] [2]

Mechanism of action

Suzetrigine operates on peripheral nerves, avoiding the addictive potential of opioids, which affect the central nervous system. [3] [4] [7] Unlike opioid medications, which reduce pain signals in the brain, suzetrigine works by closing sodium channels in peripheral nerves, inhibiting pain-signaling nerves from transmitting painful sensations to the brain. [3] [4] [7]

In pharmacological studies, suzetrigine selectively inhibited Nav1.8 channels, but not other voltage-gated sodium channels, and bound to a unique site on these sodium channels with a novel allosteric mechanism, by binding to the channel's second voltage-sensing domain, thereby stabilizing the closed state, causing tonic inhibition. It exerts its action on dorsal root ganglia. [3]

History

Vertex Pharmaceuticals announced in January 2024 that suzetrigine had successfully met several endpoints in its Phase III clinical trials. [5] The company announced in July 2024 that the FDA had accepted a New Drug Application for suzetrigine. [13] The FDA granted priority review, fast track, and breakthrough therapy designations to the application for suzetrigine. [2] [13] In January 2025, the FDA granted approval of Journavx to Vertex Pharmaceuticals, making it the first non-opioid pain medication to be approved by the FDA in two decades. [2] [14]

The manufacturer engaged in lobbying activity promoting non-opioid pain treatment and supporting the NO PAIN Act (Non-Opioids Prevent Addiction In the Nation Act). [15]

References

  1. 1 2 3 4 5 6 "Journavx- suzetrigine tablet, film coated". DailyMed. 6 February 2025. Archived from the original on 3 April 2025. Retrieved 2 April 2025.
  2. 1 2 3 4 5 6 7 8 9 10 11 "FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain" (Press release). U.S. Food and Drug Administration (FDA). 30 January 2025. Archived from the original on 7 February 2025. Retrieved 30 January 2025.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  3. 1 2 3 4 5 Osteen, Jeremiah D.; Immani, Swapna; Tapley, Tim L.; Indersmitten, Tim; Hurst, Nicole W.; Healey, Tiffany; et al. (January 2025). "Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain". Pain and Therapy. 14 (2): 655–674. doi: 10.1007/s40122-024-00697-0 . PMC   11914629 . PMID   39775738.
  4. 1 2 3 Jones, Jim; Correll, Darin J.; Lechner, Sandra M; Jazic, Ina; Miao, Xiaopeng; Shaw, David; et al. (August 2023). "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain". The New England Journal of Medicine. 389 (5): 393–405. doi:10.1056/NEJMoa2209870. PMID   37530822. S2CID   260377748.
  5. 1 2 "Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain" (Press release). Vertex. 30 January 2024. Archived from the original on 25 December 2024. Retrieved 31 January 2025– via Business Wire.
  6. ↑ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 21 February 2025. Archived from the original on 3 March 2025. Retrieved 9 March 2025.
  7. 1 2 3 4 Broadfoot, Marla (20 August 2024). "New Painkiller Could Bring Relief to Millions — without Addiction Risk". Scientific American. Archived from the original on 30 December 2024. Retrieved 31 January 2025.
  8. 1 2 3 Hang Kong, Aaron Yik; Tan, Hon Sen; Habib, Ashraf S. (September 2024). "VX-548 in the Treatment of Acute Pain". Pain Management. 14 (9): 477–486. doi:10.1080/17581869.2024.2421749. PMC  11721852. PMID   39552600.
  9. ↑ Bertoch, Todd; D’Aunno, Dominick; McCoun, Jessica; Solanki, Daneshvari; Taber, Louise; Urban, Joshua; et al. (21 March 2025). "Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials". Anesthesiology. 142 (6): 1085–1099. doi:10.1097/ALN.0000000000005460. ISSN   0003-3022. PMC   12061372 . PMID   40117446.
  10. ↑ Robinson, Christopher L.; Schatman, Michael E.; Hasoon, Jamal; Chung, Matthew; Emerick, Trent; Lo Bianco, Giuliano; et al. (2025). "Suzetrigine: Is This What We Have Been Waiting for or Just the Beginning?". Journal of Pain Research. 18: 2047–2049. doi: 10.2147/JPR.S527710 . ISSN   1178-7090. PMC   12009045 . PMID   40255364.
  11. ↑ Jones, Meaghan; Demery, Aryanna; Al-Horani, Rami A. (4 July 2025). "Suzetrigine: A Novel Non-Opioid Analgesic for Acute Pain Management—A Review". Drugs and Drug Candidates. 4 (3): 32. doi: 10.3390/ddc4030032 . ISSN   2813-2998. PMC   12337992 . PMID   40799996.
  12. ↑ Rind DM, McQueen B, Nikitin D, Lee W, DiStefano MJ, Zemplenyi A, et al. (31 March 2025). "Suzetrigine for Acute Pain; Final Report". Institute for Clinical and Economic Review.
  13. 1 2 "Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain" (Press release). Vertex. 30 July 2024. Retrieved 31 January 2025– via Business Wire.
  14. ↑ Dolgin, Elie (January 2025). "US drug agency approves potent painkiller - the first non-opioid in decades". Nature. 638 (8050): 304–305. Bibcode:2025Natur.638..304D. doi:10.1038/d41586-025-00274-1. PMID   39885357.
  15. ↑ "Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed". Nasdaq. 16 July 2025. Retrieved 15 August 2025.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.